The European Medicines Agency is currently located in London in the UK and the Agency is responsible for the scientific evaluation, supervision and safety monitoring of medicines in the EU. The EMA covers 28 EU Member States, as well as the countries of the European Economic Area, by ensuring that all medicines available on the EU market are safe, effective and of high quality.
On the 20th November 2017, 27 member states voted on where the EMA will relocate in the light of the UK leaving the EU. The decision has been made to relocate the EMA to Amsterdam in the Netherlands by 30th March 2019 at the latest.
ASUK hope the impact of the move will be minimal, to limit the disruption of the EMA’s work and operations.
Yann Le Cam, Chief Executive Officer of EURORDIS-Rare Diseases Europe, commented, “Patients are happy that the decision has now been taken, bringing to an end a long period of uncertainty and allowing the agency to plan for the future. We are pleased with the choice of Amsterdam, a city that meets the overall criteria recommended by patient and consumer groups in Europe. Amsterdam is accessible for visiting patient experts and we hope will encourage retention of current staff. This choice will support the continued presence of the patient voice at the agency and helps to preserve the value that the EMA brings to patients across the EU.”
You can find out more about the work of the EMA and the full relocation news via their website http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2017/11/news_detail_002857.jsp&mid=WC0b01ac058004d5c1
If you would like to know more about the work of EURORDIS please visit their website https://www.eurordis.org/